Pneumonia Therapeutics Market Size, Share, and Growth Report 2030
The global pneumonia treatments market was worth 13.91 billion US dollars in 2018, and it is projected to reach about 23.99 billion US dollars by 2025, at a compound annual growth rate (CAGR) of approximately 8.1% between 2019 and 2025.
Pneumonia is an inflammatory infection that affects the air sacs or alveoli in the lungs. This condition can further lead to symptoms such as a dry cough, chest pain, fever, difficulty breathing, and other symptoms. It is typically caused by germs and bacteria, and the individual who is already sick with a cold or the flu is the one who is most likely to contract it. Pneumonia is caused by a wide variety of microorganisms, including bacteria, fungus, and viruses. Infants, small children, and persons of advanced age are most vulnerable to its deadly effects. It is possible to diagnose this condition with the use of blood tests, X-rays, physical examinations, and other diagnostic tools. Getting vaccinated against pneumonia is helpful in preventing the disease, but those who already have a severe case of the illness will need to be hospitalized and treated with oxygen therapy. Antibiotics such as quinolones, macrolides, and others are typically prescribed to patients who have been diagnosed with pneumonia.
Read Related:
The global market for pneumonia treatments is expanding as a result of rising levels of air pollution and an expanding population of elderly people around the world. Environmental factors are also regarded to be important drivers for the expansion of the global market for pharmaceuticals to treat pneumonia. Fungi, viruses, and bacteria can all be encouraged to multiply by a variety of environmental pollutants, such as chemicals. Pneumonia is brought on by these germs. According to the World Health Organization, pneumonia is the cause of mortality in more than 1.6 million children under the age of five every year. On the other hand, a lack of education among the general population on the diagnosis and treatment of pneumonia, as well as the use of more traditional treatments, may in the future impede the expansion of the global market for pneumonia therapies.
On the basis of therapeutics, the global market for pneumonia therapeutics is divided into two categories: vaccines for prevention and pharmaceuticals for treatment. As a result of their high levels of efficacy and preventative benefits, the prevention vaccines held the greatest market share in terms of revenue in the year 2018. Because of the widespread availability of generic forms and the rising prevalence of antibiotic resistance, it is anticipated that the treatment pharmaceuticals segment will see moderate growth in the years to come. The market is segmented into hospital pharmacies, internet pharmacies, and retail pharmacies, depending on the route through which products are distributed.
When broken down by region, it is anticipated that North America will experience the highest CAGR throughout the course of the projection period. This expansion is likely attributable to the increased levels of air pollution and the expanding release of harmful chemicals into the environment. When compared to mortality rates for pneumonia in other age groups, the rates of children younger than four years old and individuals older than 75 years old in Europe had much higher rates of the condition. This growth is mostly attributable to the rising number of elderly people as well as conditions that are directly tied to lifestyle choices.
Some key participants operating in the global pneumonia therapeutics market include
GlaxoSmithKline
Sanofi
Merck & Co. Inc.
Novartis AG
Eli Lilly and Company
AstraZeneca
Merck & Co.
Pfizer
Baxter International Inc.
Allergan and Lupin Pharmaceuticals Inc.
This report segments the global pneumonia therapeutics market into:
Global Pneumonia Therapeutics Market: Therapeutics Analysis
Prevention Vaccines
Treatment Drugs
Global Pneumonia Therapeutics Market: Distribution Channel Analysis
Hospital pharmacy
Retail pharmacy
领英推荐
Online pharmacy
Global Pneumonia Therapeutics Market: Regional Analysis
North America
The U.S.
Europe
UK
France
Germany
Asia Pacific
China
Japan
India
Latin America
Brazil
The Middle East and Africa
Contact US
Zion Market Research
US OFFICE NO +1 (302) 444-0166
US/CAN TOLL-FREE +1 (855) 465-4651
Email:?[email protected]
Read Also: